Rapamycin (sirolimus, off-label)

Rapamycin, also known as sirolimus, is a prescription drug primarily used to prevent organ rejection after transplantation but has gained attention for its potential off-label use in promoting healthspan and treating various conditions. Studies evaluating rapamycin's off-label applications have found that it can improve aspects of healthspan in adults, enhance oral health, and address certain dermatological issues when applied topically. However, these benefits come with risks, including severe adverse events in specific contexts such as the treatment of vascular anomalies.

The drug has been linked to improved healthspan in a study involving 333 adults, where it showed potential in delaying age-related decline. Topical sirolimus was also effective for dermatological conditions, and another study found it beneficial for oral health. Despite these positive outcomes, the use of rapamycin off-label is not without risks, particularly in pediatric patients with vascular anomalies, where severe adverse events have been reported.

Rapamycin's connections to longevity research highlight its potential as a therapeutic agent for aging-related conditions. However, the drug's association with severe side effects underscores the need for careful consideration and medical supervision when used off-label.

The evidence supporting rapamycin's off-label use is still emerging, and more studies are needed to fully understand its long-term safety and efficacy.

Sources

• Evaluation of off-label rapamycin use to promote healthspan in 333 adults. (PMID:37191826)
• Off-Label Topical Application of Sirolimus (Rapamycin) for Dermatological Conditions. (PMID:40654292)
• Evaluation of off-label rapamycin use on oral health. (PMID:38839644)
• Rapamycin for longevity: the pros, the cons, and future perspectives. (PMID:40620657)
• Activated PI3K Delta Syndrome. (PMID:39899769)
• Severe adverse events during sirolimus "off-label" therapy for vascular anomalies. (PMID:33580918)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._